Stereotaxis Inc.
STXS Healthcare Medical Instruments & Supplies
Stereotaxis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.4 million, up 20.3% from fiscal 2024. In the quarter to June 2026, revenue fell 12.8%, EPS was flat and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow STXS
Stereotaxis Inc. (STXS) EV/Sales
As of 16 October 2026, Stereotaxis Inc. (STXS) trades at a EV/Sales of 3.1×. Over the past ten years it has ranged from 0.7× (January 2016) to 24.5× (June 2021); the current reading is higher than 35% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.1× | (10.57%) |
| FY2024 | 6.9× | 37.52% |
| FY2023 | 5.0× | 4.98% |
| FY2022 | 4.8× | (61.45%) |
| FY2021 | 12.4× | (0.36%) |
| FY2020 | 12.4× | 16.14% |
| FY2019 | 10.7× | 370.49% |
| FY2018 | 2.3× | 93.95% |
| FY2017 | 1.2× | 34.92% |
| FY2016 | 0.9× | 16.18% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.5× | 0.24% |
| Mar 2026 | 5.5× | (11.04%) |
| Dec 2025 | 6.1× | (33.72%) |
| Sep 2025 | 9.3× | 61.42% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DXR Daxor Corporation compare | −14.4× |
| MBOT Microbot Medical Inc. compare | −2.9× |
| NYXH Nyxoah SA compare | 0.7× |
| POCI Precision Optics Corp. compare | 0.9× |
| PDEX Pro-Dex, Inc. compare | 2.5× |
| KRMD KORU Medical Systems, Inc. compare | 2.9× |
| STXS Stereotaxis Inc. | 3.1× |
| UTMD Utah Medical Products, Inc. compare | 4.2× |
| ZTEKF Zentek Ltd. compare | 288× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)